Study of the Effectiveness and Safety of Daunorubicin /Idarubicin ± Silibinin in Treating Newly Diagnosed AML (Non-M3).

Inclusion criteria

• Newly diagnosed acute leukemia(non-M3)confirmed according to the 2018 WHO classification criteria for the diagnosis and classification of acute leukemia;
• Suitable for standard chemotherapy regimens containing idarubicin/daunorubicin;
• Patients with an expected survival time of at least 3 months as determined by the investigator;
• Voluntarily agree to participate in this study and sign the informed consent form.

Exclusion criteria

• History of other malignant tumors concurrently or previously diagnosed malignancies not under control;
• Participation in other clinical trials within one month prior to screening;
• Presence of uncontrolled cerebrovascular diseases, coagulation disorders, connective tissue diseases, or other such conditions;
• Other uncontrolled diseases that the investigator considers inappropriate for inclusion;
• Patients with psychiatric disorders or other known or suspected inability to fully comply with the study protocol;
• Pregnant or breastfeeding women;
• History of liver cirrhosis, or current active liver disease or biliary disease;
• HIV-positive individuals;
• Any other conditions that, in the investigator's judgment, may prevent the subject from completing the study or pose significant risk to the subject.